# CYCLONE 1 (NCT04408924)

> Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: abemaciclib
- Indication: heavily treated metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04408924
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Eli Lilly and Company
- Conditions: Metastatic Castration-Resistant Prostate Cancer
- Interventions: Abemaciclib
- Enrollment: 44
- Primary outcome: Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])

## Indexed commentary on CYCLONE 1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 podcast episodes
- 2 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=cyclone-1-nct04408924